Filana Therapeutics, Inc. (FLNA) Key Metrics
FLNA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $34.0M
- Enterprise value
- −$32.9M
- P/E (TTM)
- —
- Forward P/E
- 151.5
- PEG ratio
- 1.62
- Price / sales
- 2.5
- Price / book
- 0.8 10-yr median 5.2
- EV / EBITDA
- 2.1
- Dividend yield
- —
- Beta
- −0.66
FLNA key metrics, 2021–2025
Fiscal year ended December 31, 2025 · U.S. dollarsFLNA valuation Price multiples at each fiscal year-end price.
FLNA returns How much profit the business earns on the capital it uses.
FLNA per-share figures Results divided by the shares outstanding at year-end.
FLNA financial health Debt, liquidity and how easily interest is covered.
FLNA valuation history
FLNA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
FLNA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
FLNA price vs earnings per share
FLNA key metrics
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $95.6M | — | $943.9M | $1.19B | $1.72B |
| Enterprise value | $126,060 | — | $822.8M | $986.7M | — |
| Price / book | 1.3 | — | 6.9 | 5.2 | — |
| Earnings yield | −95.1% | — | −10.3% | −6.4% | −1.9% |
| Free cash flow yield | −34.3% | — | −8.7% | −6.8% | — |
| Share price at fiscal year-end | $1.98 | $2.36 | $22.51 | $29.54 | $43.70 |
| Per share | |||||
| Revenue per share | $0.00 | — | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$1.88 | — | −$2.32 | −$1.90 | −$0.82 |
| Operating cash flow per share | −$0.67 | — | −$1.96 | −$1.93 | — |
| Free cash flow per share | −$0.68 | — | −$1.97 | −$2.00 | — |
| Cash per share | $1.98 | — | $2.89 | $5.00 | — |
| Book value per share | $1.54 | — | $3.28 | $5.66 | — |
| Tangible book value per share | $1.54 | — | $3.27 | $5.64 | — |
| Capex per share | $0.01 | — | $0.01 | $0.07 | — |
| Debt per share | — | — | — | $0.00 | — |
| Shares outstanding | 48.3M | — | 41.9M | 40.2M | 39.4M |
| Change in shares outstanding | — | — | +4.3% | +2.0% | — |
| Returns & profitability | |||||
| Return on equity (ROE) | −82.7% | −17.2% | −53.3% | −33.5% | — |
| Return on invested capital (ROIC) | — | −667.9% | −389.4% | −237.1% | — |
| Return on assets (ROA) | −65.9% | −15.7% | −50.3% | −32.5% | — |
| Return on tangible assets | −76.9% | −15.5% | −64.2% | −32.6% | — |
| Financial health | |||||
| Total debt | — | — | — | $139,000 | — |
| Cash & short-term investments | $95.5M | $128.6M | $121.1M | $201.0M | — |
| Net debt | −$95.5M | −$128.6M | −$121.1M | −$200.9M | — |
| Debt / equity | — | — | — | 0.00 | — |
| Debt / assets | — | — | — | 0.00 | — |
| Current ratio | 2.23 | 11.62 | 9.13 | 29.91 | — |
| Quick ratio | 2.23 | 11.62 | 9.13 | 29.91 | — |
| Working capital | $53.9M | $124.8M | $115.4M | $204.2M | — |
| Invested capital | −$21.1M | $17.1M | $16.3M | $26.7M | — |
| Tangible asset value | $74.4M | $145.7M | $137.3M | $226.9M | — |
| Net current asset value | $53.8M | $124.7M | $115.4M | $203.9M | — |
| Graham net-net per share | $1.07 | — | $2.57 | $4.82 | — |
| Capital allocation | |||||
| Capex / depreciation | 0.62 | 0.09 | 0.27 | 2.08 | — |
| Efficiency | |||||
| Days payables outstanding | 2,739.6 | — | — | — | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | — | — |
| Payables turnover | 0.13 | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Average receivables | $533,500 | $954,500 | $962,000 | — | — |
| Average payables | $7.0M | $9.1M | $7.3M | $4.0M | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.1% | 0.3% | — |
Computed from FLNA's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
FLNA valuation and financial ratios
Filana Therapeutics earned a return on equity of −82.7% in fiscal 2025. The share count rose 22.6% from 39.4M to 48.3M over 4 years.
See the FLNA income statement, the FLNA chart for price history, or the FLNA stock overview for the latest quote and news.
FLNA key metrics FAQ
What is Filana Therapeutics's return on equity?
Filana Therapeutics's return on equity (ROE) was −82.7% in fiscal 2025: net income of -$91.0 million on average shareholders' equity of $110.1 million.
What is Filana Therapeutics's free cash flow yield?
Filana Therapeutics generated -$32.8 million of free cash flow in fiscal 2025, a free cash flow yield of −34.3% on its market value at year-end ($95.6 million).
What is Filana Therapeutics's current ratio?
Filana Therapeutics's current ratio was 2.23 at the end of fiscal 2025: current assets were 2.23 times current liabilities.